Management of obesity and cardiometabolic risk – role of phentermine/extended release topiramate
Arianne N Sweeting,1 Eddy Tabet,1 Ian D Caterson,1,2 Tania P Markovic1,2 1Department of Endocrinology, Royal Prince Alfred Hospital, Sydney, NSW, Australia; 2Boden Institute of Obesity, Nutrition, Exercise & Eating Disorders, University of Sydney, NSW, Australia Abstract: The US Food and D...
Saved in:
Main Authors: | Sweeting AN, Tabet E, Caterson ID, Markovic TP |
---|---|
Format: | article |
Language: | EN |
Published: |
Dove Medical Press
2014
|
Subjects: | |
Online Access: | https://doaj.org/article/a56e0dd14d9f45b49aa2b9cff1739cda |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Clinical utility of phentermine/topiramate (Qsymia™) combination for the treatment of obesity
by: Shin JH, et al.
Published: (2013) -
Effects of Orlistat/Phentermine versus Phentermine on Vascular Endothelial Cell Function in Obese and Overweight Adults: A Randomized, Double-Blinded, Placebo-Controlled Trial
by: Kwon YJ, et al.
Published: (2021) -
Prevalence of cardiometabolic risk factors and metabolic syndrome in obese Kuwaiti adolescents
by: Boodai SA, et al.
Published: (2014) -
Challenging obesity, diabetes, and addiction: the potential of lorcaserin extended release
by: Hurt RT, et al.
Published: (2018) -
Comparison of extended release GLP-1 receptor agonist therapy versus sitagliptin in the management of type 2 diabetes
by: Stolar MW, et al.
Published: (2013)